Abstract
Objective: To conduct an analysis of exon 53 skipping and dystrophin production and its cellular localization in muscle biopsies from patients in an ongoing trial of golodirsen (formerly SRP-4053).
Background: Golodirsen is a phosphorodiamidate morpholino oligomer (PMO) that binds and excludes exon 53 during dystrophin mRNA processing, enabling production of internally shortened dystrophin protein. A first-in-human multicenter trial is evaluating the safety, tolerability, and efficacy of golodirsen through 144 weeks of treatment in Duchenne muscular dystrophy (DMD) patients with a genetic mutation amenable to exon 53 skipping.
Design/Methods: In a preplanned interim analysis, paired muscle biopsies of the biceps brachii were obtained at baseline and Week 48 from 25 patients receiving weekly intravenous infusions of golodirsen 30 mg/kg. Biopsies were examined using a validated Western blot method to quantify dystrophin production (primary biological end point). Exon 53 skipping was evaluated using reverse transcription polymerase chain reaction (RT-PCR). An automated image analysis (MuscleMap™) used immunohistochemistry to assess dystrophin localization and sarcolemma fiber intensity.
Results: Mean percent of normal dystrophin protein increased from 0.095% at baseline to 1.019% at Week 48 (range: 0.09%–4.30%), a significant mean change of +0.924% (P<0.001). Muscle biopsy samples from all 25 patients displayed a significant increase from baseline in exon 53 skipping via RT-PCR at Week 48 (P<0.001), demonstrating the intended mechanism of action. A positive correlation between exon 53 skipping and de novo dystrophin production was observed (Spearman-r = 0.500; P=0.011). Analysis of mean fiber intensity demonstrated a significant increase from baseline in de novo dystrophin production (P<0.001) and confirmed dystrophin sarcolemma localization.
Conclusions: Golodirsen increased exon 53 skipping, dystrophin production, and dystrophin sarcolemma localization in all patients. Golodirsen is the second PMO shown to increase dystrophin expression and membrane localization through the initiation of exon skipping, further strengthening the potential utility of the PMO technology platform in DMD.
Study Supported by: Study supported by Sarepta Therapeutics.
Disclosure: Dr. Muntoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Participation to SAB meetings (Roche; Avexis and Biogen) and educational activities (Biogen). Dr. Muntoni has received research support from My institute receives support for Biogen and Roche sponsored clinical trials. Dr. Frank has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Sardone has nothing to disclose. Dr. Morgan has nothing to disclose. Dr. Schnell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Charleston has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Desjardins has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Phadke has nothing to disclose. Dr. Sewry has nothing to disclose. Dr. Popplewell has nothing to disclose. Dr. Guglieri has nothing to disclose. Dr. Bushby has nothing to disclose. Dr. Carlier has nothing to disclose. Dr. Clark has nothing to disclose. Dr. Dickson has nothing to disclose. Dr. Hogrel has nothing to disclose. Dr. Straub has nothing to disclose. Dr. Mercuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen MA, Inc, Ionis Pharmaceuticals, Inc. & F. Hoffman La-Roche Ltd. Dr. Voit has nothing to disclose. Dr. Kaye has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sarepta Therapeutics. Dr. Servais has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Avexis, Sarepta, Dynacure, Pfizer, Servier. Dr. Servais has received research support from Roche, Valerion, Dynacure.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.